Search Results
Feb 18, 2026, 13:58 ET New BofA Rewards™ Program to Reach Millions More Clients with Expanded Benefits
Qualifying accounts include:Bank of America deposit accounts: Bank of America Advantage Banking, savings, money market savings, CD and IRA accountsMerrill® investment accounts, such as the Cash Management Account (CMA) and IRA accounts529 plans appearing on your
More news about: Bank of America Corporation
Feb 18, 2026, 09:00 ET CircleCI Publishes 2026 State of Software Delivery
collected within the first 28 days of September 2025.About CircleCICircleCI is a continuous integration and continuous delivery (CI/CD) platform enabling more than two million developers at companies including Okta, Hinge, and Hugging Face to build, test, and deploy software efficiently.
More news about: Circle Internet Services, Inc., dba CircleCI
Feb 18, 2026, 09:00 ET AppSec Reality Check: 76% of Security Professionals Lack the Production Insight Needed to Secure Modern Applications
include:Although 13% of respondents use agent-based deployment, most (87%) overwhelmingly prefer agentless, package-based or simple CI/CD-based deployment;For ASPM platform users, 68% struggle to prove posture and risk to leadership or auditors, 67% cite data gaps and missing telemetry
More news about: Rein Security, Inc.
Feb 18, 2026, 07:07 ET ActiveState Unifies 79M Components to Launch World's Largest Secure Open Source Catalog
provides a trusted catalog of more than 79 million secure open source components and container images that can be consumed via artifact repository, CI/CD, IDE, or directly from ActiveState. ActiveState continuously monitors and updates the open source components to help keep companies vulnerability free.
More news about: ActiveState
Feb 18, 2026, 05:48 ET CredShields Contributes to OWASP's 2026 Smart Contract Security Priorities
including:Role-based permission validationUpgrade path simulationOracle dependency stress testingAutomated CI/CD enforcementInvariant-driven design reviewPassing an audit is not sufficient. Production resilience requires modeling adversarial
More news about: CredShields
Feb 17, 2026, 16:01 ET Axcelis Announces Financial Results for Fourth Quarter and Full Year 2025
https://register-conf.media-server.com/register/BIfd551cd8408c4503b0229e94192ef512Webcast replays will be available for 30 days following the call.Use of Non-GAAP Financial
More news about: Axcelis Technologies, Inc.
Feb 17, 2026, 11:25 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
ResQ215B, a Phase 2 clinical study evaluating a chemotherapy-free, lymphodepletion-free combination of its off-the-shelf CD19 CAR-NK cell therapy with ANKTIVA (nogapendekin alfa inbakicept) and rituximab in patients with indolent B-cell non-Hodgkin lymphoma (NHL), including
More news about: Equity Insider
Feb 17, 2026, 11:17 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
ResQ215B, a Phase 2 clinical study evaluating a chemotherapy-free, lymphodepletion-free combination of its off-the-shelf CD19 CAR-NK cell therapy with ANKTIVA (nogapendekin alfa inbakicept) and rituximab in patients with indolent B-cell non-Hodgkin lymphoma (NHL), including
More news about: Equity Insider
Feb 17, 2026, 09:00 ET Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity
than 3,800 longitudinal serum and plasma samples—and a rare set of cerebrospinal fluid (CSF) samples—from patients treated with the FDA-approved anti-CD19 CAR T-cell therapies axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel).
More news about: Metabolon, Inc.
Feb 17, 2026, 09:00 ET Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity
than 3,800 longitudinal serum and plasma samples—and a rare set of cerebrospinal fluid (CSF) samples—from patients treated with the FDA-approved anti-CD19 CAR T-cell therapies axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel).
More news about: Metabolon, Inc.
Feb 17, 2026, 07:42 ET Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation
More news about: Actinium Pharmaceuticals, Inc.
Feb 16, 2026, 10:15 ET CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
relapsed or refractory large B-cell lymphoma.Based on the target, the CAR T-cell therapy market is segmented into CD19, BCMA, and other target antigens. In 2025, the CD19 segment accounted for the largest share of the CAR T-cell therapy market. Bristol Myers Squibb expanded Breyanzi's FDA approval
More news about: MarketsandMarkets
Feb 16, 2026, 07:05 ET Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. Zemcelpro® (dorocubicel), developed by Cordex, a wholly
More news about: ExCellThera
Feb 16, 2026, 07:05 ET Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. Zemcelpro® (dorocubicel), developed by Cordex, a wholly
More news about: ExCellThera
Feb 16, 2026, 07:05 ET Zemcelpro® (dorocubicel) erhält NUB-Status 1 in Deutschland
kryokonserviertes Produkt zur hämatopoetischen Stammzelltransplantation. Es enthält zwei Komponenten: UM171-expandierte CD34+-Zellen (dorocubicel) sowie nicht expandierte CD34−-Zellen, die jeweils aus derselben Nabelschnurbluteinheit gewonnen werden.Zemcelpro® (dorocubicel), entwickelt von Cordex,
More news about: ExCellThera
Feb 16, 2026, 07:05 ET Zemcelpro® (dorocubicel) se voit attribué le statut 1 du programme NUB en Allemagne
nouveau produit cryoconservé de greffe de cellules souches hématopoïétiques comprenant deux composants, à savoir des cellules CD34+ expansées par UM171 (dorocubicel) et des cellules CD34- non expansées, chacune provenant de la même unité de sang de cordon.Zemcelpro® (dorocubicel) qui est
More news about: ExCellThera
Feb 13, 2026, 18:01 ET Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression
resistance (e.g., MYCN, ETS2, ABCB1), while high deuterium environments (300 ppm) upregulated multiple oncogenic and survival pathways (EGFR, CTNNB1, STAT3, CD44).The study confirmed that deuterium affects the same signal pathways targeted by cancer drug development, and that consuming DDW can prevent the
More news about: HYD LLC
Feb 13, 2026, 16:53 ET EUROPÄISCHE KOMMISSION GENEHMIGT UPLIZNA® VON AMGEN FÜR GENERALISIERTE MYASTHENIA GRAVIS
Erste und einzige CD19-gerichtete Therapie in Europa für Erwachsene mit Anti-AChR+ und Anti-MuSK+ gMG zugelassenUPLIZNA zeigt dauerhafte Krankheitskontrolle bei Verabreichung zweimal jährlich*THOUSAND OAKS, Kalifornien,
More news about: Amgen
Feb 13, 2026, 15:00 ET Sphingolipids Market Forecast 2025-2035: Global Value to Reach USD 1,145.6 Million by 2035 at 5.1% CAGR
share)Regions with strong momentum: North America and EuropeKey companies (named): Evonik Industries AG; CLR Berlin; CD Bioparticles; Croda International (SphingoCare™); Merck KGaA; CordenPharma International; Lipoid GmbHGet Access of Report Sample:
More news about: Future Market Insights
Feb 13, 2026, 14:41 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK UPLIZNA® OD SPOLOČNOSTI AMGEN NA LIEČBU GENERALIZOVANEJ MYASTÉNIE GRAVIS
Prvá a jediná terapia zameraná na CD19 schválená v Európe pre dospelých s protilátkami anti-AChR+ a anti-MuSK+ pri generalizovanej myasténii gravisUPLIZNA predstavuje trvalú kontrolu ochorenia s dávkovaním dvakrát ročne*THOUSAND
More news about: Amgen
Feb 13, 2026, 11:47 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN UPLIZNA ® ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИ
Первая и единственная таргетная терапия CD19, одобренная в Европе для взрослых с анти-AChR + и анти-MuSK+ гМГUPLIZNA демонстрирует устойчивый контроль заболевания при приеме препарата два раза в год*ТАУЗАНД-ОКС, Калифорния, 13
More news about: Amgen
Feb 13, 2026, 11:41 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK UPLIZNA® SPOLEČNOSTI AMGEN PRO GENERALIZOVANOU MYASTENII GRAVIS
První a jediná terapie cílená na CD19 schválená v Evropě pro dospělé s anti-AChR+ a anti-MuSK+ gMG UPLIZNA prokazuje schopnost udržet nemoc pod kontrolou při dávkování dvakrát ročně*THOUSAND OAKS, Kalifornie,
More news about: Amgen
Feb 13, 2026, 09:34 ET KOMISJA EUROPEJSKA ZATWIERDZA LEK UPLIZNA® FIRMY AMGEN W LECZENIU UOGÓLNIONEJ MIASTENII
Pierwsza i jedyna terapia ukierunkowana na CD-19 dopuszczona do obrotu w Europie dla dorosłych chorujących na uogólnioną miastenię z dodatnimi przeciwciałami przeciwko AChR i MuSK.Przy stosowaniu UPLIZNA wykazano trwałą kontrolę choroby przy dawkowaniu dwa razu w roku*.
More news about: Amgen
Feb 13, 2026, 06:04 ET VIRGIN MUSIC GROUP RECEIVES EUROPEAN COMMISSION APPROVAL FOR DOWNTOWN ACQUISITION
Artist & Label Services, Distribution, and Music Publishing. Its portfolio of businesses also includes FUGA, Downtown Artist & Label Services, CD Baby, Downtown Music Publishing and Songtrust. Following the EC's decision and the closing of the deal, Curve Royalties will be held as a separate business
More news about: Virgin Music Group
Feb 13, 2026, 05:46 ET VIRGIN MUSIC GROUP RECEIVES EUROPEAN COMMISSION APPROVAL FOR DOWNTOWN ACQUISITION
Artist & Label Services, Distribution, and Music Publishing. Its portfolio of businesses also includes FUGA, Downtown Artist & Label Services, CD Baby, Downtown Music Publishing and Songtrust. Following the EC's decision and the closing of the deal, Curve Royalties will be held as a separate business
More news about: Virgin Music Group